Merck and Endocyte's ovarian cancer drug fails in trial
(Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.
The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.
An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.
(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Pennsylvania sniper held without bail in trooper shooting |
- Global shares jump, yen slumps as BOJ cranks up stimulus |
- Special Report: Tsunami evacuees caught in $30 billion Japan money trap
- Gazprom to resume gas supply after Ukraine pays $2.2 billion